The obtained peptide-DOX conjugate can effectively target HER2-positive breast cancers and deliver DOX to nuclei faster due to the release of free DOX in the extracellular matrix through cleavage of MMP-2. The gene discussed is ERBB2; the disease is breast carcinoma.